Barclays PLC Zymeworks Inc. Transaction History

Barclays PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$4.82 - $7.7 $3,089 - $4,935	-641 Reduced 36.46%	1,117 $6,000
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $3,846 - $10,884	641 Added 57.39%	1,758 $12,000
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $72,441 - $139,874	-4,769 Reduced 81.02%	1,117 $18,000
Q3 2021 Nov 09, 2021	SELL	$27.35 - $37.28 $100,429 - $136,892	-3,672 Reduced 38.42%	5,886 $170,000
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $197,875 - $285,463	-7,467 Reduced 43.86%	9,558 $332,000
Q1 2021 May 13, 2021	BUY	$29.83 - $56.81 $462,603 - $881,009	15,508 Added 1022.28%	17,025 $537,000
Q3 2020 Nov 12, 2020	SELL	$29.21 - $46.58 $2.41 Million - $3.84 Million	-82,500 Reduced 98.19%	1,517 $71,000
Q2 2020 Aug 12, 2020	BUY	$33.67 - $40.0 $2.83 Million - $3.36 Million	84,017 New	84,017 $3.03 Million
Q1 2020 May 13, 2020	SELL	$24.28 - $49.8 $94,692 - $194,220	-3,900 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.0 - $22.49 $58,500 - $87,711	3,900 New	3,900 $86,000
Q3 2018 Nov 14, 2018	SELL	$12.21 - $16.61 $15,238 - $20,729	-1,248 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$11.13 - $21.86 $13,890 - $27,281	1,248 New	1,248 $18,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $885M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.